Phase II Study of Sorafenib + Carboplatin and Docetaxel in First Line Treatment of Stage IIIB/IV NSCLC
Status:
Completed
Trial end date:
2012-12-01
Target enrollment:
Participant gender:
Summary
This is an open-label, single institution, phase II study of Sorafenib in combination with
docetaxel and carboplatin in patients with advanced non-small cell lung cancer. Docetaxel and
carboplatin will be given on day 1 of every three week cycle. Patients will take Sorafenib
twice a day on the 1st day of treatment and continue to take the medication every day until
progression of disease, prohibitive toxicity, or patient withdrawal from the study.
Chemotherapy courses will repeat every 21 days in the absence of disease progression or
unacceptable toxicity for a total of four cycles.
Phase:
Phase 2
Details
Lead Sponsor:
Abramson Cancer Center of the University of Pennsylvania